Overexpression of Cdc20 in clinically localized prostate cancer: Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy

Cancer Biomark. 2016;16(3):351-8. doi: 10.3233/CBM-160573.


Objectives: This study was aimed to explore Cdc20 expression and its correlation with clinicopathological characteristics and biochemical recurrence (BCR) after laparoscopic radical prostatectomy (LRP) in clinically localized prostate cancer (PCa).

Methods: Cdc20 expression was examined by immunohistochemistry in 166 cases, including 60 cases of benign hyperplasia of prostate (BPH) patients treated by transurethral resection and 106 cases of consecutive PCa patients treated by LRP without neoadjuvant therapy in a single Chinese institution. The correlation with clinicopathological features and the predictive value for BCR were statistically analyzed.

Results: Cdc20 expression was detected in 52 (86.7%) BPH and 97 (91.5%) PCa samples, which was statistically insignificant (P= 0.675). The rate of patients with high expression of Cdc20 was 21.7% in BPH and 37.7% in PCa (P= 0.033). A correlation was revealed between Cdc20 expression and postoperative Gleason scores (P= 0.046), positive surgical margin (P< 0.001). BCR-free survival was significantly lower in patients with high Cdc20 expression than those with low Cdc20 expression (P= 0.018). Univariate analysis indicated pTstage, post operative Gleason score, seminal vesicle invasion, lymph node invasion, surgical margin and Cdc20 expression significantly influenced BCR. Multivariate analysis revealed that postoperative Gleason score, seminal vesicle invasion, lymph node invasion, surgical margin and Cdc20 expression were independent predictors for BCR. After stratified by Gleason score and surgical margin status, Cdc20 expression and lymph node invasion remained significant in Cox regression analysis.

Conclusions: Overexpression of Cdc20 may serve as an independent predictor for BCR in patients of clinically localized PCa undergoing LRP without neoadjuvant therapy.

Keywords: Prostatic neoplasms; biochemical recurrence; cell division cycle 20; radical prostatectomy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / biosynthesis
  • Biomarkers, Tumor / blood
  • Cdc20 Proteins / biosynthesis*
  • Humans
  • Laparoscopy
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Recurrence, Local / pathology*
  • Prostate / pathology*
  • Prostate / surgery
  • Prostate-Specific Antigen / blood
  • Prostatectomy
  • Prostatic Hyperplasia / pathology*
  • Prostatic Hyperplasia / surgery
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / surgery


  • Biomarkers, Tumor
  • Cdc20 Proteins
  • CDC20 protein, human
  • Prostate-Specific Antigen